PRME Projected Dividend Yield

Heitman Global Prime Real Estate ETF/First Trust Exchange-Traded Fund IV ( NASDAQ : PRME )

Prime Medicine is a biotechnology company committed to delivering a class of differentiated one-time curative genetic therapies, Prime Editors, to address a spectrum of diseases by deploying Prime Editing technology. Co.'s in-licensed Prime Editing technology has the ability to repair mutations. Prime Editors have two main components that act together to edit deoxyribonucleic acid (DNA): a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme, and a pegRNA, that targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.

19 YEAR PERFORMANCE RESULTS